Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORTGet Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $25.30, for a total transaction of $55,660.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Daniel N. Swisher, Jr. also recently made the following trade(s):

  • On Friday, March 1st, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $23.59, for a total transaction of $51,898.00.
  • On Thursday, February 1st, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $22.00, for a total transaction of $48,400.00.

Corcept Therapeutics Stock Performance

CORT stock opened at $25.65 on Thursday. Corcept Therapeutics Incorporated has a one year low of $20.87 and a one year high of $34.28. The company has a 50 day moving average price of $23.49 and a two-hundred day moving average price of $26.07. The stock has a market capitalization of $2.66 billion, a P/E ratio of 27.00 and a beta of 0.48.

Corcept Therapeutics (NASDAQ:CORTGet Free Report) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. Corcept Therapeutics had a net margin of 21.86% and a return on equity of 21.98%. The company had revenue of $135.41 million during the quarter, compared to analysts’ expectations of $129.27 million. During the same period in the prior year, the company posted $0.14 EPS. The firm’s revenue for the quarter was up 31.4% on a year-over-year basis. Research analysts forecast that Corcept Therapeutics Incorporated will post 0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FinTrust Capital Advisors LLC bought a new stake in Corcept Therapeutics in the third quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new position in Corcept Therapeutics during the fourth quarter worth about $32,000. Gladius Capital Management LP bought a new position in Corcept Therapeutics during the fourth quarter worth about $36,000. Lazard Asset Management LLC acquired a new stake in Corcept Therapeutics during the second quarter worth about $28,000. Finally, Pinebridge Investments L.P. acquired a new stake in Corcept Therapeutics during the 2nd quarter worth approximately $31,000. Institutional investors own 93.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. HC Wainwright decreased their price target on shares of Corcept Therapeutics from $34.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, January 2nd. Truist Financial increased their price objective on shares of Corcept Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 13th. Finally, StockNews.com upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 24th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.79.

Read Our Latest Research Report on Corcept Therapeutics

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

See Also

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.